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ABSTRACT 
In present study, LCs were formulated and evaluate for desirable properties, Sonication conditions were firstly investigated to 
determine their effects on the morphological and dimensional characteristics of liquid crystals and optimized according probe 
sonication condition (Ultra Tarrux T25), liquid crystals with reproducible narrow particle size distribution and mean particle size of 
168.0 ± 2.1 nm were obtained. The structure of the dispersed cubosomes was revealed by XRD (X-ray diffraction) and SEM 
(scanning electron microscopy) as a liquid crystalline phase. To overcome the dose frequency and increase drug loading rate, in 
vitro-dissolution, method, ultracentrifuge be firstly develop liquid crystals containing Rifampicin. The encapsulation efficiency 
determined by UV spectroscopy was 93.86 ± 0.11% and stability studies in pH 6.8 phosphate buffer solutions further confirmed that 
Rifampicin was successfully encapsulated in liquid crystals.  
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1. INTRODUCTION 
Tuberculosis (TB) is a extremely catching and deadly 
respiratory system disease 
1
 that affects millions of 
people around the world. TB treatment can take 
anywhere from six months to years to be effective. This 
length of moment in time can lead to different problems, 
including drug resistance, poor patient compliance, drug 
interactions and side effects. Improper use of first-line 
TB drugs contributes to multidrug-resistant TB 
2-3
 
.Although second-line drugs are available to treat MDR-
TB, they are more toxic, expensive and less effective 
than first-line drugs.Therefore,4it’s important to improve 
the rational and optimal use of first-line drugs to avoid 
development of rapidly emerging MDR-TB. Decreasing 
the duration of treatment and dosing frequency may help 
to avoid drug resistance to first-line drugs, and reduce 
associated treatment costs and side effects, and improve 
compliance. A drug carrier system that protects first-line 
drugs from premature degradation, promotes sustained 
release and delivers the drug at targeted tissue may help 
to improve the efficacy of TB treatment 
4
. Targeted 
delivery of drug molecules to organs or special sites is 
one of the most challenging research areas in 
pharmaceutical sciences. In colloidal delivery systems 
such as liposomes, micelles and nanoparticles a new 
frontier was opened for improving drug delivery. 
Nanoparticles can be administered via different routes of 
administration such as parenteral, oral, intraocular, 
transdermal or pulmonary inhalation. The German group 
produced the SLN by high pressure homogenization, 
while Prof. Gasco used a microemulsion technique. 
Solid lipid nanoparticles (SLNs) are produced by 
replacing the oil of an o/w emulsion by a solid lipid or a 
blend of solid lipids, i.e. the lipid particle matrix being 
solid at both room and body temperatures but most of 
problem occurred over their such as unpredictable 
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gelation tendency, high water content dispersion and 
particle growth 
5
. Nanotechnology is now being broadly 
of applied science and technology, for manipulating the 
structure of matter on molecular level at an incredibly 
small scale between 1-100nm. 
The liquid crystalline state combines properties of both 
liquid and solid states. The liquid state is associated with 
the ability to flow, whereas the solid state is 
characterized by an ordered, crystalline structure. 
Crystalline solids exhibit short as well as long-range 
order with regard to both position and orientation of the 
molecules. Liquids are amorphous in general but may 
show short-range order with respect to position and/or 
orientation 
6
. Crystalline solid characterized by long-
range positional and orientational order in three 
dimensions. Self-assemble amphiphilic molecules (i.e., 
molecules with hydrophobic and hydrophilic character) 
including some lipids in aqueous system is known to 
form a variety of liquid crystalline phases such as 
lamellar, inverted hexagonal, and inverted cubic phases 
7
. Lipid have been widely used as main constituent in 
various drug delivery systems, such as liposome, solid 
lipid nanoparticles, nanostructure lipid carriers, and lipid 
based liquid crystals. Among them, lipid-based liquid 
crystals highly ordered, thermodynamically stable 
internal nanostructure, thereby offering the potential as 
sustained drug release matrix 
8
. 
 Classification of Liquid Crystals 
9
 
LCs are differentiated on the basis of positional order 
(i.e. molecule are arranged in randomly structure lattice) 
and orientational order (i.e. molecule are mostly pointed 
in the same direction). Moreover order can be either 
short-range (only between the molecule to each other) or 
long-range (extending to larger, sometimes 
macroscopic). LCs mainly classified as Lyotropic 
(LLCs) and Thermotropic (TLCs), physicochemical 
parameters responsible for the phase transitions 
9-10
 
classification of liquid crystals are as following:  
1. Lyotropic liquid crystals, 
a) Lamellar LCs 
b) Hexagonal LCs 
c) Cubic LCs 
2. Thermotropic liquid crystals 
a) Smectic liquid crystal  
b) Nematic liquid crystal  
c) Cholesteric liquid crystals 
d) Discotic liquid crystals 
Method of preparation of LCs. 
11
 
(a) Probe Sonication 
High shear homogenization and ultrasound are 
dispersing techniques which were initially used for the 
production of solid lipid nanodispersion. However, its 
quality is compromised by the presence of 
microparticles. A pre-emulsion was obtained under 
stirring with an Ultra-Turrax T25 by adding melted lipid 
to a mixture of surfactants and water. A sonication probe 
was placed in this pre-emulsion which lead to droplet 
breakage by acoustic cavitationsand  subsequent 
formation of oil in water (o/w) nanoemulsion which 
immediately cooled down to room temperature to 
generate liquid crystals 
5
. 
Advantages 
1. Both methods are widespread and easy to handle 
2. Equipments whatever use here are very common in 
every lab 
3. Reduced shear stress 
Disadvantages 
1. Potential metal contamination 
2. Physical instability like particle growth upon 
storage 
(b) Spray drying  
To widen the applications of cubosomes in 
pharmaceutical field, dry powder precursors can be 
fabricated by spray drying and used for the preparation 
of oral solid formulations and inhalants. This approach 
was originally proposed and investigated by scientist 
Spicer. In his research, the powder precursor could be 
prepared through drying a pre-dispersed aqueous 
solution that consisted of GMO, hydrophobically 
modified starch and water or contained GMO, dextran, 
ethanol and water, and then the colloidally stable 
dispersions of nano-structured cubosomes could be 
created by hydration of the precursors. Afterward 
12
 
prepared GMO based cubosomes precursor containing 
diclofenac sodium through spray drying. The precursor 
was proven to have more effective and prolonged anti-
inflammatory and analgesic activity than pure drug when 
administered per orally; it is noteworthy, however, that 
residual solvent content is still a problem that cannot be 
ignored. 
Advantages: 
1) Spray drying technique is useful for powder 
formulation such as DPI (Dry powder inhaler, dry 
syrup). 
2) This technique used for microencapsulation. 
3) Organic solvent can use in this method. 
Disadvantages: 
1) From this method has low yield of formulation as 5-
30% out of 100%. 
2) Spray drying method is complicated as compare to 
other method 
(c) Bottom-up approach 
Compared with the top-down approach, this dilution-
based approach can produce cubosomes without 
laborious fragmentation. In other words, it needs less 
energy input. Moreover, this approach is far more 
efficient at generating small particles. The reason for this 
might relate to the forming mechanism of cubosomes. 
The dilution-based approach can be regarded as a 
process of small particles forming big particles through 
aggregation, which is analogous to the use of 
precipitation processes to produce nanoparticles, 
whereas the top-down approach is more analogous to the 
attrition of big particles. In addition, cubosomes 
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prepared through dilution show long term stability, 
which might be attributed to the homodisperse 
stabilizers onto the surface of cubosomes 
13
. Indeed, the 
use of hydrotrope can simplify the preparation process 
and produce cubosomes possessing similar or even 
better properties than those fabricated by the top-down 
approach. It should be noted, however, that this process 
via dilution is a pathway by charting trajectories on the 
ternary phase diagram (lipid and water hydrotrope), 
which requires knowledge of the full phase behavior; 
hence, the extent of dilution is difficult to control 
precisely. Owing to the addition of hydrotrope, many 
issues arise, such as the effects exerted by varying 
concentrations of hydrotrope on the physicochemical 
properties of LLC nanoparticles and the possible 
occurrence of irritation and allergic response when the 
mesophase formulations are administered. Finally, this 
bottom- up approach cannot effectively avoid forming 
vesicles. 
Advantages: 
1) Lower energy input. 
2) Less time consuming process. 
3) At high concentration prevent the formation of LCs. 
4) No need the organic solvent 
Disadvantages: 
1) Milky white formulation formed. 
2) Hydrotrope which shows allergic reaction when the 
mesophase formulation administered orally. 
(d) Heat treatment 
The coexistence of cubosomes with vesicles is 
speculated to provide multiphase manipulation of the 
sustained release of drugs; hence, to better investigate 
the release behavior of plain mesophases, vesicles 
should be eliminated as much as possible. In this case, 
heat treatment can be regarded as a good approach. Note 
that in the strictest sense, heat treatment is not an 
integrated process for the manufacture of cubosomes 
because it only promotes the transformation from non-
cubic vesicles to well-ordered cubic particles. The 
dispersed particles, therefore, can be produced by a 
simple processing scheme comprising a homogenization 
and heat-treatment step. From the reported studies, heat 
treatment could cause a decrease in the small particle 
size fraction that corresponded to vesicles and form 
more cubic phases with narrow particle distribution and 
good colloidal stability 
14
. Taking the whole process of 
preparation into account, it is obvious that the transition 
takes place during the procedure of heat treatment. The 
reason for transition could be speculated as an elevated 
temperature giving rise to a reduction in solubility and 
stability. When the temperature was below cloud point, 
the surfactant had a high solubility and thus the particles 
could exist stably and the phenomenon of fusion was 
hardly observed. Once reaching cloud point, the 
solubility of surfactant decreased notably and a notable 
fast fusion among vesicles would occur. Although 
masses of vesicles can transform to cubic nanoparticles 
through heat treatment, it does not mean that all the LLC 
systems are suitable for this procedure in particular, the 
systems loading drugs that cannot provide sufficient 
stability under the condition of high temperature (usually 
above 120°C), such as some proteins and temperature-
sensitive drugs are not suitable. 
Advantages: 
1) It produced good colloidal dispersion. 
2) It can reduce particle size. 
Disadvantages: 
1) Degradation of thermo sensitive substance due to 
formation of aggregate. 
Reduction of stability of formulation 
(e) Top-down approach 
The extreme viscous bulk phase is prepared by mixing 
structure-forming lipids with stabilizers, and then the 
resultant is dispersed into aqueous solution through the 
input of high energy such as high-pressure 
homogenization (HPH), sonication or shearing to form 
LLC nanoparticles. At present, HPH is the most 
extensively used technique in the preparation of LLC 
nanoparticles 
13
. Cubosomes. Based on the results 
observed, the concentration of F127 and temperature 
during HPH were regarded as crucially important 
parameters. Recently, a novel approach of shearing was 
proposed to fabricate LLC nanoparticles using a 
laboratory built- Shearing apparatus. Compared with the 
well-established ultrasonication approach, the shearing 
treatment could effectively prepare more stable and 
homogeneous cubosomes or hexosomes with high 
content of the hydrophobic phase (oil + lipophilic 
additives) within a short time (less than one minute). It 
seems that the preparation procedure is simple enough to 
be realized conveniently. In fact, the operation units in 
this procedure require several cycles to achieve the 
desired Nanoparticles with appropriate characteristics 
and the high-energy input is also regarded as a barrier to 
the temperature resensitive ingredients 
14
. 
Advantages: 
1) Lower impact to overall organization. 
2) Visibility of formulation changes is clear.  
3) No need of organic solvent. 
4) Simple method as compare to other method such as 
spray drying. 
Disadvantages: 
1) Solution provides limited coverage in the first 
phase. 
2) High energy input required. 
3) Time consuming process. 
Applications of liquid crystals system: 
15
 
Therapeutic compounds of diverse physicochemical 
properties such as analgesic, antibiotics, antifungal, 
anticancer, vitamins, antiasthamatics, 
immunosuppressive etc. monoglyceride based cubosome 
dispersion can be proposed for topical used, such as for 
precutaneous or mucosal applications. Because of the 
microbicidal properties of monoglycerides, could be 
used to design intravaginal treatment of sexually 
transmitted diseases caused by viruses (e.g. HSV, HIV) 
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or by bacteria (e.g. Chlamydia trachomatis and 
neisseriagenorrticae). The cubosome technology is used 
to develop a synthetic venix the chessy white substance 
that coats infants in late gestation to help premature 
infants who are born without it. E vernix is a complex 
mixture of lipid (fat), proteins and water. Cubosome can 
also be used for controlled release application. 
Cubosome particles are used as oil water emulsion 
stabilizers and pollutant absorbants in cosmetics. More 
recent use is about personal cure product areas as varied 
as skin care, hair care, cosmetics and antiperspirant.  
2. MATERIALS AND METHODS 
The model Rifampicin was provided from Healthy Life 
Pharma Pvt. Ltd. Mumbai. Glycerol Monooleate was 
purchased from Abitec Corporation 1530 Jackson St 
Janesville, WI 53546 P- F68 (Poloxamer 188) was 
purchased from HI Media Lab. Pvt. Ltd. Mumbai. And 
ethanol from MerckSpecialities Pvt. Ltd., Worli, 
Mumbai.  
Methods 
Drug-Excipient Interaction Study 
Fourier transformed infrared spectroscopy: 
IR spectroscopy was used to determine the molecular 
interaction between Excipient and drug. The all physical 
mixtures and drug sample were mixed with dried KBr in 
ratio 1:100. Then small fraction of mixture was 
compressed on automatic IR press (KimayaEngg. Thane, 
India) pressure 10 tones to form transparent pellet. Then 
the IR spectrum of pellet was taken on FTIR 
spectrophotometer.  
Method of Preparation of Liquid Crystals (LCs): 
7-11
 
 
Figure 1: Preparation of liquid crystals  
Formulation of liquid crystals by Probe Sonication 
method (Ultra-Turrax T25) 
probe sonication method a pre-emulsion was obtained 
under stirring with an Ultra-Turrax T25 by adding 
melted lipid to a mixture of surfactants and water. A 
sonication probe was placed in this pre-emulsion which 
lead to droplet breakage by acoustic cavitationsand  
subsequent formation of oil in water (o/w) nanoemulsion 
which immediately cooled down to room temperature to 
generate Rifampicin-LCs. we obtain the expected 
particle size and PDI by using above technique. 
7-11
 
Table 1: Composition of formulation batches 
Sr.No Batch no Drug (mg) GMO (%) Poloxamer (%) Ethanol (%) Water (%) 
1 B1 100 5.5 0.5 2 2 
2 B2 100 5.5 1.0 2 2 
3 B3 100 5.5 1.5 2 2 
4 B4 100 6 0.5 2 2 
5 B5 100 6 1.0 2 2 
6 B6 100 6 1.5 2 2 
7 B7 100 6.5 0.5 2 2 
8 B8 100 6.5 1.0 2 2 
9 B9 100 6.5 1.5 2 2 
 
Preparation of Rifampicin loaded liquid crystals: 
For the preparation of Glycerol monooleate-based liquid 
crystals loaded with rifampicin, ingredients were taken 
according to above table. Rifampicin was firstly 
dissolved in 2 ml of ethanol. Glycerol 
monooleate(GMO),  P188 (P F-68), ethanol and water at 
a different ratios of (w/w). GMO was melted on a 
magnetig stirrer with heating plate with the temperature 
60-80ºC. Then, the Rifampicin solution was added 
slowly on magnetic stirringat same temp.  After 
complete addition of rifampicin solution stirred it 
continuously until total dissolution. Required amount of 
water was gradually added to melted mixture with 
magnetic stirrer for 20 minutes. The resulting viscous 
dispersions was sonicated/homogenized by using a 
probe sonicater/high-speed homogenizer (Ultra Turrax 
T25) at certain high rpm to obtain andispersion of the 
LCs. Kept it for 24-48 hrs to form LC gel. 
11
 
Preparation of Granules of Rifampicin loaded LCs 
as Final Dosage Form 
The preparation of granules is carried out by wet 
granulation with sieving method by using sieve no 22. 
Silicon dioxide (Aerosil) is used to form the dump mass. 
First the certain amount of SD was taken in mortar then 
LCs formulation is added slowly until the dump mass is 
obtained. Prepared dump mass is pass through the sieve 
and obtained granules are allow for drying at room 
temp.    
Characterization of Liquid crystals 
Particle Size Measurements: 
7-16
 
GMO+Stabilizer    
Aqueous phase 
Liquid 
Crystals 
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The particle size was determined by photon correlation 
spectroscopy using a Zetasizer Nano® (Malvern 
Instruments, Malvern, UK) at 25°C. Samples were 
diluted with deionize water prior to the measurement. 
Particle size was analyzed by the dispersion technology 
software provided by Malvern instruments. The 
polydispersity index (PDI), which was dimensionless 
number indicating the width of the size distribution, was 
also obtained. 
7-16
 
Zeta potential of the Rifampicin–LCs: 17 
Zeta potential measurements were run at 25C with 
electric ﬁeld strength of 23 V/m, using Zetasizer (Nano 
ZS 90, Malvern Instruments, UK). To determine the zeta 
potential, samples of Rifampicin-LCs were diluted and 
placed in electrophoretic cell. The zeta potential was 
calculated as described by Helmholtz–Smoluchowski 
equation. 
17
 
Scanning Electron Microscopy. 
18
 
The surface morphology of liquid crystal nanoparticles 
was studied using a scanning electron microscopy (JSM 
6390®, JEOL DATUM Ltd., Japan). Lyophilized 
powder of optimized formulations was dusted onto 
double-sided tape on an aluminum stub and coated with 
gold using a cold sputter coater in SEM chamber to a 
thickness of 400 Å, and then photomicrographs were 
captured by operating at an accelerating voltage of 15 
kV electron beam. 
18
 
X-Ray Diffraction 
9
 
X-ray diffraction patterns of Rifampicin, Physical 
mixture and LCs containing Rifampicin(final dosage 
form) were obtained using X-ray Diffractometer 
(Brucker Axs, D8 Advance, and Germany) and Cu-Kα 
line as a source of radiation which was operated at the 
voltage 40 kV and the current 30 mA. All samples were 
measured in the 2θ angle range between 100 and 600 
with a scanning rate of 30 /min and a step size of 0.020. 
9
 
In vitro dissolution study 
The drug release study was carried out using a 
dissolution study apparatus (USP Apparatus I, basket 
type). The dissolution medium was having pH 1.2 (0.1N 
HCl) and pH 6.8 buffer. The dissolution experiments 
were conducted at 37 ± 0.5°C at a basket rate of 100 
rpm for 12 hours. Sampling was performed with interval 
of 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours. first two 
hours in pH 1.2 buffer (0.1N HCl) and next 3 to 12 
hours in pH 6.8 buffer  .Detection of Rifampicin 
concentration in samples was identifying by using UV- 
spectrophotometer at 331 nm. 
19
 
3. RESULT AND CONCLUSION 
Drug-Excipient Interaction Study 
Fourier transformed infrared spectroscopy 
 
 
Figure 2: IR Spectra of Drug 
 
Figure 3: IR Spectra of GMO 
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Figure 4: IR Spectra of Physical mixture 
Table 2: Drug excipient interaction studies by IR spectroscopy 
Functional  
Group 
Observed peak at wave number 
Drug  GMO Physical mixture 
-OH Stretch 3385.81 3637.75 3456.55 
-CH Stretch 2827.74 30001.24 2850.88 
C=C Stretch - 1646.35 - 
C-O Stretch  1051.20 1099.46 
N-H Stretch 2881.75 - 3456.55 
C-N Stretch 1656.91 - 1251.84 
 
There is no interaction was observed between drug and 
excipient by detection functional groups in physical 
mixture 
X –ray diffraction pattern (XRD) 
The Liquid crystals phase can be fragmented into stable 
submicron sized particles, which retain the internal 
structure of the original liquid crystals. As illustrated in 
Figure 3 and 4, pure cefixime trihydrate show fewer 
peaks as compare the Rifampicin-loaded liquid crystals 
showed X-ray diffraction (XRD) peaks in the X-ray 
diffraction curves, with the same spacing ratio. 
 
 
Figure 5: XRD of pure drug Rifampicin 
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Figure 6: XRD of physical mixture  
 
Figure 7: XRD of optimized formulation 
 
Scanning Electron Microscopy (SEM) 
 
Figure 8: SEM image of liquid crystals granules loaded 
with rifampicin.  
In order to further investigate the liquid crystals 
structure of the rifampicin GMO-based liquid crystals 
granules and liquid crystals containing rifampicin probe 
sonicated by ultra Tarrux T25 (B6), the formulations 
were examined by SEM. 
Figure 8, showed the image of liquid crystal granules 
which contained reverse cubic structure with a mean 
particle size of about 168 nm close to that observed by 
laser diffraction. The image of liquid crystals containing 
Cefixime trihydrate with typical hexagonal 
characterization and a mean particle size of about 168 
nm with PDI 0.367 
Zeta potential 
Zeta potential of optimized Rifampicin-LCs was found 
to be – 40.1 as seen in Figure 5. It possesses negative 
surface charges due to the negatively charged CT. In 
addition to surfactant (Poloxamer 188) were also 
negatively charged. It is currently admitted that zeta 
potentials upto -40.1 mV, are optimum and less than (-
60) mV, are required for full electrostatic stabilization.
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Figure 5: Zeta potential value of the optimized Rifampicin-LCs batch 
Mean Particle Size 
Particle size of optimized Rifampicin-LCs was found to be 168 nm as seen in Figure 6.  
 
Figure 6: Particle size of the optimized Rifampicin-LCs batch 
In-vitro dissolution Study of optimized formulation 
batch (B6): 
In vitro drug release is determined for LCs loaded with 
Rifampicin in 1.2 pH and 6.8 pH phosphate buffer for 1-
12 hours. 
Table 3: In-vitro release data of optimized batch (B6) 
Time   %CDR 
0 0 
0.5 2.857143 
1 5.730159 
2 8.603175 
3 22.17857 
4 28.13459 
5 37.87302 
6 44.33135 
7 54.15774 
8 62.78737 
9 69.37996 
10 77.67394 
11 86.42857 
12 90.2295 
 
 
Figure 7: Graphical Representation of In-vitro release 
of optimized formulation batch (B6) 
In-vitro Comparative dissolution study of optimized 
formulation batch with Rifampicin marketed 
formulation (Rifampicin 150): 
For the determination of Comparison study study the 
marketed formulation of rifampicin 150 mg capsule was 
selected and the in-vitro release was determined in 1.2 
pH and 6.8 pH buffer for 12 hours. In vitro drug release 
0 
20 
40 
60 
80 
100 
0 2 4 6 8 10 12 14 
%CDR 
%CDR 
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study of the optimized Rifampicin-LCs formulation. In 
the in vitro dissolution study show rifampicin loaded 
liquid crystal was improved the release rate and 
solubility as compared to marketed formulation. 
Table 4: In-vitro release data of marketed formulation 
and optimize batch (B6) 
Time 
Marketed 
Formulation 
Optimize 
batch (B6) 
0 0 0 
0.5 0 2.857 
1 4.285 5.730 
2 7.166 8.603 
3 18.813 22.178 
4 24.334 28.134 
5 30.301 37.873 
6 35.135 44.331 
7 42.366 54.157 
8 48.459 62.787 
9 52.667 69.379 
10 56.392 77.673 
11 60.396 86.428 
12 65.077 90.229 
 
Figure 8: Graphical representation of in-vitro release of 
optimizes batch and marketed formulation. 
CONCLUSION 
Rifampicin was formulated as GMO based liquid 
crystals in an attempt to reverse cubic LCs having 
sustained release. An optimized formulation of GMO 
liquid crystals containing Rifampicin was characterized 
by the, particle size analysis, zeta potential and 
characterization was carried out by SEM and X-ray 
diffraction, following In-vitro dissolution and In-vitro. 
GMO-based cubosomes provided significant in the 
sustained drug delivery which helps to reduce frequency 
of dose. 
 
 
REFERENCES 
1. Kaufmann S.H. and McMichael, A.J., Annulling a dangerous 
liaison: vaccination strategies against AIDS and 
tuberculosis. Nature medicine, 2005; 11(4s):S33. 
2. Sun Z., Zhang J., Song H., Zhang X., Li Y., Tian M., Liu Y., 
Zhao Y., Li C., Concomitant increases in spectrum and level 
of drug resistance in Mycobacterium tuberculosis isolates. 
International Journal of Tuberculosis Lung Disorders. 2010; 
14:1436-1441. 
3. Caminero J.A., Sotgiu G., Zumla A., Migliori G.B., Best drug 
treatment for multidrug-resistant and extensively drug-resistant 
tuberculosis. The Lancet Infectious Diseases. 2010; 10(9):621-
629.  
4. Pooja D., Tunki L., Kulhari H., Reddy B.B. and Sistla R., 
2015. Characterization, biorecognitive activity and stability of 
WGA grafted lipid nanostructures for the controlled delivery 
of Rifampicin. Chemistry and physics of lipids, 193, pp.11-17.. 
5. Muller F., Salonen A. and Glatter O. Monoglyceride-based 
cubosomes stabilized by laponite: Separating the effects of 
stabilizer, pH and temperature. Colloids Surf A: Physico Eng 
Asp, 2010; 358:50-56. 
6. Gaikwad P.P. and Desai M.T. Liquid crystalline phase and its 
pharma applications. Intl J Pharma Res Rev, 2013; 2:40-52. 
7. Lai J., Chen J., Lu Y., Sun J., Hu F., Yin Z. and Wu W. 
Glyceratemonooleate/poloxamer 407 cubic nanoparticles as 
oral drug delivery systems I. In vitro evaluation and enhanced 
oral bioavailability of the poorly water soluble drug 
Simvastatin. AAPS PharmSci Tech, 2009; 10:960-966. 
8. Chen Y., Ma P and Gui S. Cubic and hexagonal liquid crystals 
as drug delivery systems. BioMed Research International, 
2014; 1-12 
9. Omray L.K. Liquid crystals as novel vesicular delivery 
system: Review. Curr Trends TechnolSci, 2013; 2:347-353. 
10. Fong W.K, Dong, Y.D and Boyd, B.J., Drug delivery in 
Lyotropic Liquid Crystals: Applications of X-ray scattering in 
pharmaceutical science, Langmuir Int. J. Pharm. 2011. 
11. Guo C., Wang J., Cao F., Lee R.J. and Zhai G. Lyotropic 
liquid crystal systems in drug delivery. Drug Del Today, 2010; 
15:1032-1040. 
12. Shah M.H. and Paradkar A. Cubic liquid crystalline 
glycerylmonooleate matrices for oral delivery of enzyme. Intl 
J Pharma 2005; 294:161-171. 
13. Spicer P.T. Progress in liquid crystalline dispersions: 
Cubosomes. CurrOpin Colloid Inter Sci, 2005; 10:274-279. 
14. Worle G., Siekmann B. and Bunjes H. Effect of drug loading 
on the transformation of vesicular into cubic nanoparticles 
during heat treatment of aqueous monoolein/poloxamer 
dispersions. Euro J PharmaBiopharma, 2006; 63:128-133. 
15. Boyd B.J., Whittaker D.V., Khoo S.-M. and Davey G. 
Lyotropic liquid crystalline phases formed from glycerate 
surfactants as sustained release drug delivery systems. Intl J 
Pharma 2006; 309:218-226. 
16. Tilley A.J., Drummond C.J. and Boyd B.J. Disposition and 
association of the steric stabilizer Pluronic
®
 F127 in lyotropic 
liquid crystalline nanostructured particle dispersions. J Colloid 
Inter Sci, 2013; 392:288-296. 
17. Serpe, L., Catalano, M. G., Cavalli, R., Ugazio, E., Bosco, O., 
Canaparo, R., Muntoni, E., Frairia, R., Gasco, M. R., Eandi, 
M. and Zara, G. P. Cytotoxicity of anticancer drugs 
incorporated in solid lipid nanoparticles on HT-29 colorectal 
cancer cell line. Eur. J. Pharm. Biopharm., 2004; 58:673– 80. 
18. Tan S. W., Billa N., Roberts C. R. and Burleyc J. C. Surfactant 
effects on the physical characteristics of Amphotericin B-
containing nanostructured lipid carriers. Colloids Surf. A: 
Physicochem. Eng. Aspects. 2010; 372:73– 9. 
19. Siddique S., Khanam J. and Bigoniya P., Development of 
sustained release capsules containing “coated matrix granules 
of metoprolol tartrate”.  Aaps Pharmscitech, 2010; 11(3):1306-
1314.
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0 2 4 6 8 10 12 14 
%
 C
D
R
 
Time (hr) 
Marketed Formulation 
Optimize batch (B6) 
